Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Xinyu Ge, Sheng Ma, Shu Yan, Yali Wu, Chong Chen, Chongzhuang Tang, Yan Zhan, Yi-cong Bian, Kai Shen, Sheng Feng, Xuehu Gao, Dafang Zhong, Hua Zhang, Li-yan Miao & Xing-xing Diao. (2023) Mass balance study of [14C]SHR0302, a selective and potent JAK1 inhibitor in humans. Xenobiotica 53:2, pages 69-83.
Read now
Read now
Qing Zhang, Hu-Xinyue Duan, Ruo-Lan Li, Jia-Yi Sun, Jia Liu, Wei Peng, Chun-Jie Wu & Yong-Xiang Gao. (2021) Inducing Apoptosis and Suppressing Inflammatory Reactions in Synovial Fibroblasts are Two Important Ways for Guizhi-Shaoyao-Zhimu Decoction Against Rheumatoid Arthritis. Journal of Inflammation Research 14, pages 217-236.
Read now
Read now
Maria Gabriella Raimondo, Martina Biggioggero, Lavinia Agra Coletto, Andreas Ramming, Roberto Caporali & Ennio Giulio Favalli. (2021) Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. Expert Review of Clinical Pharmacology 14:6, pages 661-670.
Read now
Read now
Giulia Roda, Arianna Dal Buono, Marjorie Argollo & Silvio Danese. (2020) JAK selectivity: more precision less troubles. Expert Review of Gastroenterology & Hepatology 14:9, pages 789-796.
Read now
Read now
Horace Massa, Spyros Y Pipis, Temilade Adewoyin, Athanasios Vergados, Sudeshna Patra & Georgios D Panos. (2019) Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. Clinical Ophthalmology 13, pages 1761-1777.
Read now
Read now
Spyridon Koronis, Panagiotis Stavrakas, Miltiadis Balidis, Nikolaos Kozeis & Paris G Tranos. (2019) Update in treatment of uveitic macular edema. Drug Design, Development and Therapy 13, pages 667-680.
Read now
Read now
Articles from other publishers (27)
Peeyush Prasad, Sneha Verma, Surbhi, Nirmal Kumar Ganguly, Ved Chaturvedi & Shivani Arora Mittal. (2022) Rheumatoid arthritis: advances in treatment strategies. Molecular and Cellular Biochemistry 478:1, pages 69-88.
Crossref
Crossref
Ansab Akhtar, Jaspreet Kaur, Mei Nee Chiu & Sangeeta Pilkhwal Sah. 2023. Drug Repurposing for Emerging Infectious Diseases and Cancer. Drug Repurposing for Emerging Infectious Diseases and Cancer
395
421
.
Shuhao Zhou, Weiwei Mao, Yuan Su, Xuejian Zheng, Wenyuan Qian, Meiyue Shen, Ningli Shan, Yaoshuang Li, Degang Wang, Shouting Wu, Tiemin Sun & Liwei Mu. (2022) Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis. Journal of Medicinal Chemistry 65:24, pages 16716-16740.
Crossref
Crossref
Yeke Wu, Yi Liu, Lele Zhang, Lan Wen & Yunfei Xie. (2022) Aconiti lateralis radix praeparata total alkaloids exert anti-RA effects by regulating NF-κB and JAK/STAT signaling pathways and promoting apoptosis. Frontiers in Pharmacology 13.
Crossref
Crossref
Yu Zhuang, Qiushuang Sun, Tian Jing, Jia Liu, Haitao Meng, Yaqi Cao, Zhixia Qiu, Junen Sun & Ning Li. (2022) Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib. European Journal of Pharmaceutical Sciences 175, pages 106211.
Crossref
Crossref
Md Fulbabu Sk, Nisha Amarnath Jonniya, Rajarshi Roy & Parimal Kar. (2022) Unraveling the Molecular Mechanism of Recognition of Selected Next-Generation Antirheumatoid Arthritis Inhibitors by Janus Kinase 1. ACS Omega 7:7, pages 6195-6209.
Crossref
Crossref
Bharath Kumar Gajjela & Ming-Ming Zhou. (2022) Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling. Drug Discovery Today 27:2, pages 390-400.
Crossref
Crossref
Yasmin Adel, Mohamed Sabry, Amr Mohamed El-Sabbagh & Yousra Sadeq. (2021) JAK2 mutation may predict response and guide first line treatment in rheumatoid arthritis. The Egyptian Journal of Internal Medicine 33:1.
Crossref
Crossref
Peter Nash. (2021) Clinical use of Jak 1 inhibitors for rheumatoid arthritis. Rheumatology 60:Supplement_2, pages ii31-ii38.
Crossref
Crossref
Fabiola Atzeni, Javier Rodríguez-Carrio, Călin D. Popa, Michael T. Nurmohamed, Gabriella Szűcs & Zoltán Szekanecz. (2021) Cardiovascular effects of approved drugs for rheumatoid arthritis. Nature Reviews Rheumatology 17:5, pages 270-290.
Crossref
Crossref
Rebecca Begley, Kacey Anderson, Timothy R. Watkins, Winnie Weng, Lorraine Ampaw, Ann Qin, Brian P. Kearney & Anita Mathias. (2020) Lack of Drug‐Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers. Clinical Pharmacology in Drug Development 10:4, pages 376-383.
Crossref
Crossref
Olivier Lortholary, Mario Fernandez-Ruiz, John W Baddley, Oriol Manuel, Xavier Mariette & Kevin L Winthrop. (2020) Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Annals of the Rheumatic Diseases 79:12, pages 1532-1543.
Crossref
Crossref
Bergithe E. Oftedal & Anette S. B. Wolff. (2020) New era of therapy for endocrine autoimmune disorders. Scandinavian Journal of Immunology 92:5.
Crossref
Crossref
Vijayabhaskar Veeravalli, Ranjeet P. Dash, Jennifer A. Thomas, R. Jayachandra Babu, Lakshmi Mohan Vamsi Madgula & Nuggehally R. Srinivas. (2020) Critical Assessment of Pharmacokinetic Drug–Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment. Drug Safety 43:8, pages 711-725.
Crossref
Crossref
Y. H. Lee & G. G. Song. (2019) Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trialsVergleich der Wirksamkeit und Sicherheit von Tofacitinib und Filgotinib bei Patienten mit aktiver rheumatoider Arthritis: eine Bayes-Netzwerk-Metaanalyse randomisierter kontrollierter Studien. Zeitschrift für Rheumatologie 79:6, pages 590-603.
Crossref
Crossref
Ping Xin, Xiaoyun Xu, Chengjie Deng, Shuang Liu, Youzhi Wang, Xuegang Zhou, Hongxing Ma, Donghua Wei & Shiqin Sun. (2020) The role of JAK/STAT signaling pathway and its inhibitors in diseases. International Immunopharmacology 80, pages 106210.
Crossref
Crossref
Qing Zhang, Wei Peng, Shujun Wei, Daneng Wei, Ruolan Li, Jia Liu, Lanyu Peng, Shuang Yang, Yongxiang Gao, Chunjie Wu & Xufeng Pu. (2019) Guizhi-Shaoyao-Zhimu decoction possesses anti-arthritic effects on type II collagen-induced arthritis in rats via suppression of inflammatory reactions, inhibition of invasion & migration and induction of apoptosis in synovial fibroblasts. Biomedicine & Pharmacotherapy 118, pages 109367.
Crossref
Crossref
Katie Bechman, Mark Yates & James B. Galloway. (2019) The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors. Pharmacological Research 147, pages 104392.
Crossref
Crossref
Feng Jiang, Linghe Zang, Xiuqi Miao, Fang Jia, Jie Wang, Minglin Zhu, Ping Gong, Nan Jiang & Xin Zhai. (2019) Design, synthesis and anti-inflammatory evaluation of novel pyrrolo[2,3-d]pyrimidin derivatives as potent JAK inhibitors. Bioorganic & Medicinal Chemistry 27:18, pages 4089-4100.
Crossref
Crossref
Francesca Musumeci, Chiara Greco, Ilaria Giacchello, Anna Lucia Fallacara, Munjed M. Ibrahim, Giancarlo Grossi, Chiara Brullo & Silvia Schenone. (2019) An Update on JAK Inhibitors. Current Medicinal Chemistry 26:10, pages 1806-1832.
Crossref
Crossref
Anja Dullius, Claudia Monfroni Rocha, Stefan Laufer, Claucia Fernanda Volken de Souza & Márcia Inês Goettert. (2019) Are peptides a solution for the treatment of hyperactivated JAK3 pathways?. Inflammopharmacology 27:3, pages 433-452.
Crossref
Crossref
Agnès Fernández-Clotet, Jesús Castro-Poceiro & Julián Panés. (2019) JAK Inhibition: The Most Promising Agents in the IBD Pipeline?. Current Pharmaceutical Design 25:1, pages 32-40.
Crossref
Crossref
V. Chemes, O. Abrahamovych, U. Abrahamovych, L. Tsyhanyk & S. Guta. (2019) Peculiarities of Calcium-Phosphorus Metabolism and Bone State in Patients with Rheumatoid Arthritis: Pathogenesis, Diagnosis and Principles of Differential Treatment (Literature Review and Clinical Case Description). Lviv clinical bulletin 1:25, pages 51-62.
Crossref
Crossref
Florence Namour, Liesbeth Fagard, Annegret Van der Aa, Pille Harrison, Yan Xin & Chantal Tasset. (2018) Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor. British Journal of Clinical Pharmacology 84:12, pages 2779-2789.
Crossref
Crossref
Katherine R Tuttle, Frank C BrosiusIIIIII, Sharon G Adler, Matthias Kretzler, Ravindra L Mehta, James A Tumlin, Yoshiya Tanaka, Masakazu Haneda, Jiajun Liu, Maria E Silk, Tracy E Cardillo, Kevin L Duffin, Joseph V Haas, William L Macias, Fabio P Nunes & Jonathan M Janes. (2018) JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrology Dialysis Transplantation 33:11, pages 1950-1959.
Crossref
Crossref
Charles J. Malemud. (2018) The role of the JAK/STAT signal pathway in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease 10:5-6, pages 117-127.
Crossref
Crossref
Etienne C.E. Wang, Zhenpeng Dai & Angela M. Christiano. (2018) Novel therapies for alopecia areata: The era of rational drug development. Journal of Allergy and Clinical Immunology 141:2, pages 499-504.
Crossref
Crossref